Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Plasma and tumoral glypican-3 levels are correlated in patients with hepatitis C virus-related hepatocellular carcinoma.

Shimizu Y, Mizuno S, Fujinami N, Suzuki T, Saito K, Konishi M, Takahashi S, Gotohda N, Tada T, Toyoda H, Kumada T, Miura M, Suto K, Yamaji T, Matsuda T, Endo I, Nakatsura T.

Cancer Sci. 2020 Feb;111(2):334-342. doi: 10.1111/cas.14251. Epub 2019 Dec 28.

2.

Ki67 expression and localization of T cells after neoadjuvant therapies as reliable predictive markers in rectal cancer.

Imaizumi K, Suzuki T, Kojima M, Shimomura M, Sakuyama N, Tsukada Y, Sasaki T, Nishizawa Y, Taketomi A, Ito M, Nakatsura T.

Cancer Sci. 2020 Jan;111(1):23-35. doi: 10.1111/cas.14223. Epub 2019 Dec 18.

3.

Type I Interferon Delivery by iPSC-Derived Myeloid Cells Elicits Antitumor Immunity via XCR1+ Dendritic Cells.

Tsuchiya N, Zhang R, Iwama T, Ueda N, Liu T, Tatsumi M, Sasaki Y, Shimoda R, Osako Y, Sawada Y, Kubo Y, Miyashita A, Fukushima S, Cheng Z, Nakaki R, Takubo K, Okada S, Kaneko S, Ihn H, Kaisho T, Nishimura Y, Senju S, Endo I, Nakatsura T, Uemura Y.

Cell Rep. 2019 Oct 1;29(1):162-175.e9. doi: 10.1016/j.celrep.2019.08.086.

4.

Efficacy of the NCCV Cocktail-1 vaccine for refractory pediatric solid tumors: A phase I clinical trial.

Akazawa Y, Hosono A, Yoshikawa T, Kaneda H, Nitani C, Hara J, Kinoshita Y, Kohashi K, Manabe A, Fukutani M, Wakabayashi M, Sato A, Shoda K, Shimomura M, Mizuno S, Nakamoto Y, Nakatsura T.

Cancer Sci. 2019 Dec;110(12):3650-3662. doi: 10.1111/cas.14206. Epub 2019 Nov 19.

5.

Heat shock protein 105 peptide vaccine could induce antitumor immune reactions in a phase I clinical trial.

Shimizu Y, Yoshikawa T, Kojima T, Shoda K, Nosaka K, Mizuno S, Wada S, Fujimoto Y, Sasada T, Kohashi K, Bando H, Endo I, Nakatsura T.

Cancer Sci. 2019 Oct;110(10):3049-3060. doi: 10.1111/cas.14165. Epub 2019 Sep 19.

6.

First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors.

Shitara K, Ueha S, Shichino S, Aoki H, Ogiwara H, Nakatsura T, Suzuki T, Shimomura M, Yoshikawa T, Shoda K, Kitano S, Yamashita M, Nakayama T, Sato A, Kuroda S, Wakabayashi M, Nomura S, Yokochi S, Ito S, Matsushima K, Doi T.

J Immunother Cancer. 2019 Jul 24;7(1):195. doi: 10.1186/s40425-019-0677-y.

7.

Next-Generation Cancer Immunotherapy Targeting Glypican-3.

Shimizu Y, Suzuki T, Yoshikawa T, Endo I, Nakatsura T.

Front Oncol. 2019 Apr 10;9:248. doi: 10.3389/fonc.2019.00248. eCollection 2019. Review.

8.

Usefulness of serum microRNA as a predictive marker of recurrence and prognosis in biliary tract cancer after radical surgery.

Akazawa Y, Mizuno S, Fujinami N, Suzuki T, Yoshioka Y, Ochiya T, Nakamoto Y, Nakatsura T.

Sci Rep. 2019 Apr 11;9(1):5925. doi: 10.1038/s41598-019-42392-7.

9.

Higher human lymphocyte antigen class I expression in early-stage cancer cells leads to high sensitivity for cytotoxic T lymphocytes.

Akazawa Y, Nobuoka D, Takahashi M, Yoshikawa T, Shimomura M, Mizuno S, Fujiwara T, Nakamoto Y, Nakatsura T.

Cancer Sci. 2019 Jun;110(6):1842-1852. doi: 10.1111/cas.14022. Epub 2019 May 18.

10.

Selective elimination of undifferentiated human pluripotent stem cells using pluripotent state-specific immunogenic antigen Glypican-3.

Okada M, Tada Y, Seki T, Tohyama S, Fujita J, Suzuki T, Shimomura M, Ofuji K, Kishino Y, Nakajima K, Tanosaki S, Someya S, Kanazawa H, Senju S, Nakatsura T, Fukuda K.

Biochem Biophys Res Commun. 2019 Apr 9;511(3):711-717. doi: 10.1016/j.bbrc.2019.02.094. Epub 2019 Mar 1.

PMID:
30827508
11.

Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy.

Minagawa A, Yoshikawa T, Yasukawa M, Hotta A, Kunitomo M, Iriguchi S, Takiguchi M, Kassai Y, Imai E, Yasui Y, Kawai Y, Zhang R, Uemura Y, Miyoshi H, Nakanishi M, Watanabe A, Hayashi A, Kawana K, Fujii T, Nakatsura T, Kaneko S.

Cell Stem Cell. 2018 Dec 6;23(6):850-858.e4. doi: 10.1016/j.stem.2018.10.005. Epub 2018 Nov 15.

12.

Profiling the Tumour Immune Microenvironment in Pancreatic Neuroendocrine Neoplasms with Multispectral Imaging Indicates Distinct Subpopulation Characteristics Concordant with WHO 2017 Classification.

Takahashi D, Kojima M, Suzuki T, Sugimoto M, Kobayashi S, Takahashi S, Konishi M, Gotohda N, Ikeda M, Nakatsura T, Ochiai A, Nagino M.

Sci Rep. 2018 Sep 3;8(1):13166. doi: 10.1038/s41598-018-31383-9.

13.

[Enhancement of Cytotoxic T Lymphocytes(CTLs)Infiltration into the Cancer Tissues].

Akazawa Y, Suzuki T, Nakatsura T.

Gan To Kagaku Ryoho. 2018 Feb;45(2):227-231. Japanese.

PMID:
29483410
14.

Organoids with cancer stem cell-like properties secrete exosomes and HSP90 in a 3D nanoenvironment.

Eguchi T, Sogawa C, Okusha Y, Uchibe K, Iinuma R, Ono K, Nakano K, Murakami J, Itoh M, Arai K, Fujiwara T, Namba Y, Murata Y, Ohyama K, Shimomura M, Okamura H, Takigawa M, Nakatsura T, Kozaki KI, Okamoto K, Calderwood SK.

PLoS One. 2018 Feb 7;13(2):e0191109. doi: 10.1371/journal.pone.0191109. eCollection 2018.

15.

Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors.

Tsuchiya N, Hosono A, Yoshikawa T, Shoda K, Nosaka K, Shimomura M, Hara J, Nitani C, Manabe A, Yoshihara H, Hosoya Y, Kaneda H, Kinoshita Y, Kohashi K, Yoshimura K, Fujinami N, Saito K, Mizuno S, Nakatsura T.

Oncoimmunology. 2017 Sep 27;7(1):e1377872. doi: 10.1080/2162402X.2017.1377872. eCollection 2017.

16.

Cancer immunotherapy-targeted glypican-3 or neoantigens.

Shimizu Y, Suzuki T, Yoshikawa T, Tsuchiya N, Sawada Y, Endo I, Nakatsura T.

Cancer Sci. 2018 Mar;109(3):531-541. doi: 10.1111/cas.13485. Epub 2018 Feb 14. Review.

17.

Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma.

Tsuchiya N, Yoshikawa T, Fujinami N, Saito K, Mizuno S, Sawada Y, Endo I, Nakatsura T.

Oncoimmunology. 2017 Jul 11;6(10):e1346764. doi: 10.1080/2162402X.2017.1346764. eCollection 2017.

18.

Cancer peptide vaccine targeted glypican-3 antigen.

Nakatsura T.

Nihon Rinsho. 2017 Feb;75(2):257-262. Japanese.

PMID:
30562861
19.

Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma.

Ofuji K, Saito K, Suzuki S, Shimomura M, Shirakawa H, Nobuoka D, Sawada Y, Yoshimura M, Tsuchiya N, Takahashi M, Yoshikawa T, Tada Y, Konishi M, Takahashi S, Gotohda N, Nakamoto Y, Nakatsura T.

Oncotarget. 2017 Jun 6;8(23):37835-37844. doi: 10.18632/oncotarget.14271.

20.

Efficacy of glypican-3-derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma.

Suzuki S, Sakata J, Utsumi F, Sekiya R, Kajiyama H, Shibata K, Kikkawa F, Nakatsura T.

Oncoimmunology. 2016 Sep 30;5(11):e1238542. doi: 10.1080/2162402X.2016.1238542. eCollection 2016.

21.

A Novel High-Throughput 3D Screening System for EMT Inhibitors: A Pilot Screening Discovered the EMT Inhibitory Activity of CDK2 Inhibitor SU9516.

Arai K, Eguchi T, Rahman MM, Sakamoto R, Masuda N, Nakatsura T, Calderwood SK, Kozaki K, Itoh M.

PLoS One. 2016 Sep 13;11(9):e0162394. doi: 10.1371/journal.pone.0162394. eCollection 2016.

22.

Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients.

Sawada Y, Yoshikawa T, Ofuji K, Yoshimura M, Tsuchiya N, Takahashi M, Nobuoka D, Gotohda N, Takahashi S, Kato Y, Konishi M, Kinoshita T, Ikeda M, Nakachi K, Yamazaki N, Mizuno S, Takayama T, Yamao K, Uesaka K, Furuse J, Endo I, Nakatsura T.

Oncoimmunology. 2016 Jan 19;5(5):e1129483. doi: 10.1080/2162402X.2015.1129483. eCollection 2016 May.

23.

Prognostic significance of FOXM1 expression and antitumor effect of FOXM1 inhibition in synovial sarcomas.

Maekawa A, Kohashi K, Kuda M, Iura K, Ishii T, Endo M, Nakatsura T, Iwamoto Y, Oda Y.

BMC Cancer. 2016 Jul 20;16:511. doi: 10.1186/s12885-016-2542-4.

24.

Era of cancer immunotherapy has come.

Nakatsura T.

Nihon Rinsho Meneki Gakkai Kaishi. 2016;39(3):164-71. doi: 10.2177/jsci.39.164. Review. Japanese.

25.

BCR-ABL-specific CD4+ T-helper cells promote the priming of antigen-specific cytotoxic T cells via dendritic cells.

Ueda N, Zhang R, Tatsumi M, Liu TY, Kitayama S, Yasui Y, Sugai S, Iwama T, Senju S, Okada S, Nakatsura T, Kuzushima K, Kiyoi H, Naoe T, Kaneko S, Uemura Y.

Cell Mol Immunol. 2018 Jan;15(1):15-26. doi: 10.1038/cmi.2016.7. Epub 2016 May 15.

26.

Identification of glypican-3-derived long peptides activating both CD8+ and CD4+ T cells; prolonged overall survival in cancer patients with Th cell response.

Sayem MA, Tomita Y, Yuno A, Hirayama M, Irie A, Tsukamoto H, Senju S, Yuba E, Yoshikawa T, Kono K, Nakatsura T, Nishimura Y.

Oncoimmunology. 2015 Aug 31;5(1):e1062209. eCollection 2016.

27.

Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate.

Sugai S, Yoshikawa T, Iwama T, Tsuchiya N, Ueda N, Fujinami N, Shimomura M, Zhang R, Kaneko S, Uemura Y, Nakatsura T.

Int J Oncol. 2016 May;48(5):1794-804. doi: 10.3892/ijo.2016.3403. Epub 2016 Feb 19.

28.

Enhancement of antitumor effect by peptide vaccine therapy in combination with anti-CD4 antibody: Study in a murine model.

Fujinami N, Yoshikawa T, Sawada Y, Shimomura M, Iwama T, Sugai S, Kitano S, Uemura Y, Nakatsura T.

Biochem Biophys Rep. 2016 Feb 19;5:482-491. doi: 10.1016/j.bbrep.2016.02.010. eCollection 2016 Mar.

29.

Vaccination with liposome-coupled glypican-3-derived epitope peptide stimulates cytotoxic T lymphocytes and inhibits GPC3-expressing tumor growth in mice.

Iwama T, Uchida T, Sawada Y, Tsuchiya N, Sugai S, Fujinami N, Shimomura M, Yoshikawa T, Zhang R, Uemura Y, Nakatsura T.

Biochem Biophys Res Commun. 2016 Jan 1;469(1):138-143. doi: 10.1016/j.bbrc.2015.11.084. Epub 2015 Nov 23.

30.

Expression of Forkhead box M1 in soft tissue leiomyosarcoma: Clinicopathologic and in vitro study using a newly established cell line.

Maekawa A, Kohashi K, Setsu N, Kuda M, Iura K, Ishii T, Matsunobu T, Nakatsura T, Iwamoto Y, Oda Y.

Cancer Sci. 2016 Jan;107(1):95-102. doi: 10.1111/cas.12846. Epub 2016 Jan 12.

31.

FOXM1 expression in rhabdomyosarcoma: a novel prognostic factor and therapeutic target.

Kuda M, Kohashi K, Yamada Y, Maekawa A, Kinoshita Y, Nakatsura T, Iwamoto Y, Taguchi T, Oda Y.

Tumour Biol. 2016 Apr;37(4):5213-23. doi: 10.1007/s13277-015-4351-9. Epub 2015 Nov 9.

PMID:
26553361
32.

Biomarkers for the early diagnosis of hepatocellular carcinoma.

Tsuchiya N, Sawada Y, Endo I, Saito K, Uemura Y, Nakatsura T.

World J Gastroenterol. 2015 Oct 7;21(37):10573-83. doi: 10.3748/wjg.v21.i37.10573. Review.

33.

Potentiality of immunotherapy against hepatocellular carcinoma.

Tsuchiya N, Sawada Y, Endo I, Uemura Y, Nakatsura T.

World J Gastroenterol. 2015 Sep 28;21(36):10314-26. doi: 10.3748/wjg.v21.i36.10314. Review.

34.

Suppression of postsurgical recurrence of hepatocellular carcinoma treated with autologous formalin-fixed tumor vaccine, with special reference to glypican-3.

Kawashima I, Kawashima Y, Matsuoka Y, Fujise K, Sakai H, Takahashi M, Yoshikawa T, Nakatsura T, Ishihara T, Ohno T.

Clin Case Rep. 2015 Jun;3(6):444-7. doi: 10.1002/ccr3.279. Epub 2015 Apr 17.

35.

Time-lapse imaging assay using the BioStation CT: a sensitive drug-screening method for three-dimensional cell culture.

Sakamoto R, Rahman MM, Shimomura M, Itoh M, Nakatsura T.

Cancer Sci. 2015 Jun;106(6):757-65. doi: 10.1111/cas.12667. Epub 2015 May 6.

36.

Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancer.

Imamura Y, Mukohara T, Shimono Y, Funakoshi Y, Chayahara N, Toyoda M, Kiyota N, Takao S, Kono S, Nakatsura T, Minami H.

Oncol Rep. 2015 Apr;33(4):1837-43. doi: 10.3892/or.2015.3767. Epub 2015 Jan 29.

PMID:
25634491
37.

A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancer.

Ofuji K, Tada Y, Yoshikawa T, Shimomura M, Yoshimura M, Saito K, Nakamoto Y, Nakatsura T.

Int J Oncol. 2015 Feb;46(2):497-504. doi: 10.3892/ijo.2014.2787. Epub 2014 Dec 1.

38.

Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes.

Sawada Y, Yoshikawa T, Shimomura M, Iwama T, Endo I, Nakatsura T.

Int J Oncol. 2015 Jan;46(1):28-36. doi: 10.3892/ijo.2014.2737. Epub 2014 Oct 30.

39.

Glypican 3 expression in pediatric malignant solid tumors.

Kinoshita Y, Tanaka S, Souzaki R, Miyoshi K, Kohashi K, Oda Y, Nakatsura T, Taguchi T.

Eur J Pediatr Surg. 2015 Feb;25(1):138-44. doi: 10.1055/s-0034-1393961. Epub 2014 Oct 26.

PMID:
25344940
40.

Large-scale expansion of γδ T cells and peptide-specific cytotoxic T cells using zoledronate for adoptive immunotherapy.

Yoshikawa T, Takahara M, Tomiyama M, Nieda M, Maekawa R, Nakatsura T.

Int J Oncol. 2014 Nov;45(5):1847-56. doi: 10.3892/ijo.2014.2634. Epub 2014 Sep 3.

41.

Detection and preliminary evaluation of circulating tumor cells in the peripheral blood of patients with eight types of cancer using a telomerase-specific adenovirus.

Yabusaki M, Sato J, Kohyama A, Kojima T, Nobuoka D, Yoshikawa T, Sawada Y, Murakami K, Gohda K, Okegawa T, Nakamura M, Takamatsu K, Ito M, Kaneko K, Nakatsura T.

Oncol Rep. 2014 Nov;32(5):1772-8. doi: 10.3892/or.2014.3436. Epub 2014 Aug 22.

42.

Identification of a novel HLA-A 02:01-restricted cytotoxic T lymphocyte epitope derived from the EML4-ALK fusion gene.

Yoshimura M, Tada Y, Ofuzi K, Yamamoto M, Nakatsura T.

Oncol Rep. 2014 Jul;32(1):33-9. doi: 10.3892/or.2014.3198. Epub 2014 May 19.

43.

Disulfiram eradicates tumor-initiating hepatocellular carcinoma cells in ROS-p38 MAPK pathway-dependent and -independent manners.

Chiba T, Suzuki E, Yuki K, Zen Y, Oshima M, Miyagi S, Saraya A, Koide S, Motoyama T, Ogasawara S, Ooka Y, Tawada A, Nakatsura T, Hayashi T, Yamashita T, Kaneko S, Miyazaki M, Iwama A, Yokosuka O.

PLoS One. 2014 Jan 13;9(1):e84807. doi: 10.1371/journal.pone.0084807. eCollection 2014.

44.

Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma.

Ofuji K, Saito K, Yoshikawa T, Nakatsura T.

J Hepatocell Carcinoma. 2014 May 21;1:35-42. doi: 10.2147/JHC.S48517. eCollection 2014. Review.

45.

Identification of HLA-A2 or HLA-A24-restricted CTL epitopes for potential HSP105-targeted immunotherapy in colorectal cancer.

Sawada Y, Komori H, Tsunoda Y, Shimomura M, Takahashi M, Baba H, Ito M, Saito N, Kuwano H, Endo I, Nishimura Y, Nakatsura T.

Oncol Rep. 2014 Mar;31(3):1051-8. doi: 10.3892/or.2013.2941. Epub 2013 Dec 20.

46.

Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: two case reports.

Suzuki S, Shibata K, Kikkawa F, Nakatsura T.

Hum Vaccin Immunother. 2014;10(2):338-43. doi: 10.4161/hv.27217. Epub 2013 Nov 21.

47.

Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican‑3‑derived peptide.

Tada Y, Yoshikawa T, Shimomura M, Sawada Y, Sakai M, Shirakawa H, Nobuoka D, Nakatsura T.

Int J Oncol. 2013 Oct;43(4):1019-26. doi: 10.3892/ijo.2013.2044. Epub 2013 Jul 31.

48.

Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination: an autopsy case.

Sawada Y, Yoshikawa T, Fujii S, Mitsunaga S, Nobuoka D, Mizuno S, Takahashi M, Yamauchi C, Endo I, Nakatsura T.

Hum Vaccin Immunother. 2013 Jun;9(6):1228-33. doi: 10.4161/hv.24179. Epub 2013 Mar 6.

49.

Peptide vaccines for hepatocellular carcinoma.

Nobuoka D, Yoshikawa T, Sawada Y, Fujiwara T, Nakatsura T.

Hum Vaccin Immunother. 2013 Jan;9(1):210-2. doi: 10.4161/hv.22473.

50.

Peptide intra-tumor injection for cancer immunotherapy: enhancement of tumor cell antigenicity is a novel and attractive strategy.

Nobuoka D, Yoshikawa T, Fujiwara T, Nakatsura T.

Hum Vaccin Immunother. 2013 Jun;9(6):1234-6. doi: 10.4161/hv.23990. Epub 2013 Feb 14. Review.

Supplemental Content

Loading ...
Support Center